Analyst Viewpoint
Surge in prevalence of blood-related disorders and technological advancements in testing procedures are propelling the hematology diagnostics market size. Fully automated laboratory hematology analyzers are gaining traction among end-users as they offer streamlined workflows, increased efficiency, and enhanced accuracy in blood analysis.
Governments in various countries are investing in the development of healthcare infrastructure, thereby offering lucrative hematology diagnostics market opportunities to vendors. Comprehensive and user-friendly platforms along with advanced hematology diagnostic tests are gaining popularity among end-users. Vendors are addressing the varied demands of healthcare professionals, fostering long-term relationships, and establishing a strong market position.
Hematology is defined as the diagnostic classification of blood cells and the subsequent identification of blood-forming organ and blood disease abnormalities. The numbers of WBC, RBC, and platelets are all computed. The study of hematologic diseases involves disease monitoring, prognosis, diagnosis, and screening.
Hematology testing devices have made significant strides in their evolution, progressing from diagnosing and monitoring illnesses to conducting blood cell examinations and counts. Automation has further advanced to detect microscopic cell populations in order to diagnose rare blood illnesses. The use of automation has led to a decline in the need for labor and the availability of faster results.
Automation of the hematological assessment procedure has been achieved through various technological approaches, including electrical impedance, flow cytometry, and fluorescence flow, enabling more efficient and accurate blood cell analysis. The convergence of these technologies has increased test yield and productivity in the global hematology diagnostics industry. The number of tests performed or test volume is predicted to increase due to technological advancements in disease detection. This, in turn, is propelling the hematology diagnostics market progress.
Rise in awareness regarding blood-related disorders is boosting demand for specialized hematology lab services. According to the Leukemia & Lymphoma Society, in the U.S., one person is diagnosed with blood cancer every three minutes. Over 173,000 people in the country were expected to be diagnosed with leukemia, lymphoma, or myeloma by 2022. Leukemia, lymphoma, and myeloma were projected to account for more than 10.2% of the 1.7 million new cancer cases diagnosed In the U.S. in 2022. Over 1.3 million people in the country are estimated to have leukemia, lymphoma, or myeloma, or to be in remission.
Rise in cases of various blood disorders, such as anemia, thalassemia, and hemophilia, is augmenting the hematology diagnostics market value. According to National Institutes of Health (NIH), anemia affects around 29% of women and 38% of pregnant women each year. Furthermore, hematologic tests can now identify diabetes, hypotension, and hypoglycemia, all of which are marked by elevated blood glucose levels. This makes them increasingly popular in diabetic-heavy countries.
The blood transferrin receptor test, which was developed recently, allows for more accurate blood analysis for the determination of iron levels in the patient population. Serum ferritin, a 480 kDa multisubunit protein, represents the body's iron storage pool. A drop in serum ferritin level frequently indicates that iron stores have been exhausted. Iron deficiency anemia has become easily distinguishable from chronic disease anemia using serum transferrin receptor testing. Upon comparison to earlier diagnostic approaches, this technology has made hematology diagnostics more accessible and economical.
A newly discovered strain of human herpesvirus has been outlined to play a crucial role in myeloma, a cancer of the cell plasma. Additional thrombotic risk factors have also been identified, leading to more accurate diagnoses. Factor V and prothrombin gene mutations, and hyperhomocysteinaemia are all classified as crucial risk factors. Modern DNA probe arrays can also potentially allow rapid automated detection of mutations. Antisense therapy, ribozyme technology, and other cutting-edge hematology diagnostic techniques have also been developed in the market. Such developments are expected to spur the hematology diagnostics market growth in the near future.
According to the latest hematology diagnostics market forecast, North America is expected to hold largest share from 2023 to 2031. High prevalence of blood-related diseases is fueling the market dynamics of the region. According to The Centers for Disease Control and Prevention (CDC), Sickle Cell Disease (SCD) affects approximately 100,000 people in the U.S. SCD occurs among about 1 out of every 365 Black or African-American births.
The industry in Asia Pacific is projected to grow at the fastest rate during the forecast period. Hemoglobinopathies are the most common genetic disorders among people living in Southeast Asia. In Eastern Asia, alfa and beta thalassemia cases are rather common. Thus, rise in cases of hemoglobinopathies is driving the market statistics in Asia Pacific.
Major hematology diagnostics companies are embracing automation and advanced technologies, such as artificial intelligence and machine learning, to improve the efficiency and accuracy of hematological diagnostics. They are also collaborating with healthcare institutions, research organizations, and industry stakeholders to increase their hematology diagnostics market share.
Abbott, Sysmex Corporation, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Horiba, Ltd., HemoCue AB, and Danaher Corporation are key entities operating in this market.
Each of these players has been profiled in the hematology diagnostics market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 4.6 Bn |
| Market Forecast Value in 2031 | US$ 7.6 Bn |
| Growth Rate (CAGR) | 5.6% |
| Forecast Period | 2023 to 2031 |
| Historical Data Available for | 2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Regions Covered |
|
| Countries Covered |
|
| Market Segmentatio |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 4.6 Bn in 2022
It is projected to grow at a CAGR of 5.6% from 2023 to 2031
Surge in prevalence of blood-related disorders and technological advancements in testing procedures
The diagnostic laboratories end-user segment held largest share in 2022
North America held largest share in 2022
Abbott, Sysmex Corporation, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Horiba, Ltd., HemoCue AB, and Danaher Corporation
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hematology Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hematology Diagnostics Market Analysis and Forecast, 2023–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Hematology Diagnostics Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2023–2031
6.3.1. Hematology Instruments
6.3.1.1. Hematology Analyzers
6.3.1.1.1. Fully-automated Hematology Analyzers
6.3.1.1.2. Semi-automated Hematology Analyzers
6.3.1.2. Flow Cytometers
6.3.1.3. Others
6.3.2. Hematology Consumables
6.3.2.1. Reagents
6.3.2.2. Stains
6.3.2.3. Controls & Calibrators
6.3.2.4. Others
6.4. Market Attractiveness Analysis, by Product Type
7. Global Hematology Diagnostics Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2023–2031
7.3.1. Diagnostic Laboratories
7.3.2. Hospitals & Clinics
7.3.3. Academic Institutes
7.3.4. Others
7.4. Market Attractiveness Analysis, by End-user
8. Global Hematology Diagnostics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2023–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Hematology Diagnostics Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Product Type, 2023–2031
9.3.1. Hematology Instruments
9.3.1.1. Hematology Analyzers
9.3.1.1.1. Fully-automated Hematology Analyzers
9.3.1.1.2. Semi-automated Hematology Analyzers
9.3.1.2. Flow Cytometers
9.3.1.3. Others
9.3.2. Hematology Consumables
9.3.2.1. Reagents
9.3.2.2. Stains
9.3.2.3. Controls & Calibrators
9.3.2.4. Others
9.4. Market Value Forecast, by End-user, 2023–2031
9.4.1. Diagnostic Laboratories
9.4.2. Hospitals & Clinics
9.4.3. Academic Institutes
9.5. Market Value Forecast, by Country, 2023–2031
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Product Type
9.6.2. By End-user
9.6.3. By Country
10. Europe Hematology Diagnostics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Product Type, 2023–2031
10.3.1. Hematology Instruments
10.3.1.1. Hematology Analyzers
10.3.1.1.1. Fully-automated Hematology Analyzers
10.3.1.1.2. Semi-automated Hematology Analyzers
10.3.1.2. Flow Cytometers
10.3.1.3. Others
10.3.2. Hematology Consumables
10.3.2.1. Reagents
10.3.2.2. Stains
10.3.2.3. Controls & Calibrators
10.3.2.4. Others
10.4. Market Value Forecast, by End-user, 2023–2031
10.4.1. Diagnostic Laboratories
10.4.2. Hospitals & Clinics
10.4.3. Academic Institutes
10.4.4. Others
10.5. Market Value Forecast, by Country/Sub-region, 2023–2031
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Product Type
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific Hematology Diagnostics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Product Type, 2023–2031
11.3.1. Hematology Instruments
11.3.1.1. Hematology Analyzers
11.3.1.1.1. Fully-automated Hematology Analyzers
11.3.1.1.2. Semi-automated Hematology Analyzers
11.3.1.2. Flow Cytometers
11.3.1.3. Others
11.3.2. Hematology Consumables
11.3.2.1. Reagents
11.3.2.2. Stains
11.3.2.3. Controls & Calibrators
11.3.2.4. Others
11.4. Market Value Forecast, by End-user, 2023–2031
11.4.1. Diagnostic Laboratories
11.4.2. Hospitals & Clinics
11.4.3. Academic Institutes
11.4.4. Others
11.5. Market Value Forecast, by Country/Sub-region, 2023–2031
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Product Type
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America Hematology Diagnostics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Product Type, 2023–2031
12.3.1. Hematology Instruments
12.3.1.1. Hematology Analyzers
12.3.1.1.1. Fully-automated Hematology Analyzers
12.3.1.1.2. Semi-automated Hematology Analyzers
12.3.1.2. Flow Cytometers
12.3.1.3. Others
12.3.2. Hematology Consumables
12.3.2.1. Reagents
12.3.2.2. Stains
12.3.2.3. Controls & Calibrators
12.3.2.4. Others
12.4. Market Value Forecast, by End-user, 2023–2031
12.4.1. Diagnostic Laboratories
12.4.2. Hospitals & Clinics
12.4.3. Academic Institutes
12.4.4. Others
12.5. Market Value Forecast, by Country/Sub-region, 2023–2031
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Product Type
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa Hematology Diagnostics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Product Type, 2023–2031
13.3.1. Hematology Instruments
13.3.1.1. Hematology Analyzers
13.3.1.1.1. Fully-automated Hematology Analyzers
13.3.1.1.2. Semi-automated Hematology Analyzers
13.3.1.2. Flow Cytometers
13.3.1.3. Others
13.3.2. Hematology Consumables
13.3.2.1. Reagents
13.3.2.2. Stains
13.3.2.3. Controls & Calibrators
13.3.2.4. Others
13.4. Market Value Forecast, by End-user, 2023–2031
13.4.1. Diagnostic Laboratories
13.4.2. Hospitals & Clinics
13.4.3. Academic Institutes
13.4.4. Others
13.5. Market Value Forecast, by Country/Sub-region, 2023–2031
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Product Type
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Abbott
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Sysmex Corporation
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. F. Hoffmann-La Roche Ltd.
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Beckman Coulter, Inc.
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Bio-Rad Laboratories, Inc.
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Siemens Healthineers AG
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Horiba, Ltd.
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. HemoCue AB
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Danaher Corporation
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
List of Tables
Table 01: Global Hematology Diagnostics Market Size (US$ Mn) Forecast, by Product Type, 2023–2031
Table 02: Global Hematology Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2023–2031
Table 03: Global Hematology Diagnostics Market Size (US$ Mn) Forecast, by Region, 2023–2031
Table 04: North America Hematology Diagnostics Market Size (US$ Mn) Forecast, by Country, 2023–2031
Table 05: North America Hematology Diagnostics Market Size (US$ Mn) Forecast, by Product Type, 2023–2031
Table 06: North America Hematology Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2023–2031
Table 07: Europe Hematology Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 8: Europe Hematology Diagnostics Market Size (US$ Mn) Forecast, by Product Type, 2023–2031
Table 9: Europe Hematology Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2023–2031
Table 10: Asia Pacific Hematology Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 11: Asia Pacific Hematology Diagnostics Market Size (US$ Mn) Forecast, by Product Type, 2023–2031
Table 12: Asia Pacific Hematology Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2023–2031
Table 13: Latin America Hematology Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 14: Latin America Hematology Diagnostics Market Size (US$ Mn) Forecast, by Product Type, 2023–2031
Table 15: Latin America Hematology Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2023–2031
Table 16: Middle East & Africa Hematology Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 17: Middle East & Africa Hematology Diagnostics Market Size (US$ Mn) Forecast, by Product Type, 2023–2031
Table 18: Middle East & Africa Hematology Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2023–2031
List of Figures
Figure 01: Global Hematology Diagnostics Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2031
Figure 02: Global Hematology Diagnostics Market Revenue (US$ Mn), by Product Type, 2022
Figure 03: Global Hematology Diagnostics Market Value Share, by Product Type, 2022
Figure 04: Global Hematology Diagnostics Market Revenue (US$ Mn), by End-user, 2022
Figure 05: Global Hematology Diagnostics Market Value Share, by End-user, 2022
Figure 06: Global Hematology Diagnostics Market Value Share, by Region, 2022
Figure 07: Global Hematology Diagnostics Market Value (US$ Mn) Forecast, 2023–2031
Figure 8: Global Hematology Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2031
Figure 9: Global Hematology Diagnostics Market Attractiveness Analysis, by Product Type, 2022-2031
Figure 10: Global Hematology Diagnostics Market Value Share Analysis, by End-user, 2023 and 2031
Figure 11: Global Hematology Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
Figure 12: Global Hematology Diagnostics Market Value Share Analysis, by Region, 2023 and 2031
Figure 13: Global Hematology Diagnostics Market Attractiveness Analysis, by Region, 2022-2031
Figure 14: North America Hematology Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 15: North America Hematology Diagnostics Market Attractiveness Analysis, by Country, 2023–2031
Figure 16: North America Hematology Diagnostics Market Value Share Analysis, by Country, 2023 and 2031
Figure 17: North America Hematology Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2031
Figure 18: North America Hematology Diagnostics Market Value Share Analysis, by End-user, 2023 and 2031
Figure 19: North America Hematology Diagnostics Market Attractiveness Analysis, by Product Type, 2022–2031
Figure 20: North America Hematology Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 21: Europe Hematology Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 22: Europe Hematology Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 23: Europe Hematology Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 24: Europe Hematology Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2031
Figure 25: Europe Hematology Diagnostics Market Value Share Analysis, by End-user, 2023 and 2031
Figure 26: Europe Hematology Diagnostics Market Attractiveness Analysis, by Product Type, 2022–2031
Figure 27: Europe Hematology Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 28: Asia Pacific Hematology Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 29: Asia Pacific Hematology Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 30: Asia Pacific Hematology Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 31: Asia Pacific Hematology Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2031
Figure 32: Asia Pacific Hematology Diagnostics Market Value Share Analysis, by End-user, 2023 and 2031
Figure 33: Asia Pacific Hematology Diagnostics Market Attractiveness Analysis, by Product Type, 2022–2031
Figure 34: Asia Pacific Hematology Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 35: Latin America Hematology Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 36: Latin America Hematology Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 37: Latin America Hematology Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 38: Latin America Hematology Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2031
Figure 39: Latin America Hematology Diagnostics Market Value Share Analysis, by End-user, 2023 and 2031
Figure 40: Latin America Hematology Diagnostics Market Attractiveness Analysis, by Product Type, 2022–2031
Figure 41: Latin America Hematology Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 42: Middle East & Africa Hematology Diagnostics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 43: Middle East & Africa Hematology Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 44: Middle East & Africa Hematology Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 45: Middle East & Africa Hematology Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2031
Figure 46: Middle East & Africa Hematology Diagnostics Market Value Share Analysis, by End-user, 2023 and 2031
Figure 47: Middle East & Africa Hematology Diagnostics Market Attractiveness Analysis, by Product Type, 2022–2031
Figure 48: Middle East & Africa Hematology Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Hematology Diagnostics Market
